California law permits care to be delivered by telehealth, and Business and Professions Code section 2290.5 does not require an initial in-person examination
This article selected 50 newborns with pneumonia from Qiqihar Medical University, Second Affiliated Hospital, to ensure the representativeness and consistency of the sample
Immediate medical attention is necessary if patients experience: Persistent vomiting lasting more than 24 hours or inability to keep down any fluids Signs of dehydration , including decreased urination, dark urine, dizziness, dry mouth, or confusion Severe abdominal pain , particularly if constant, sharp, or radiating to the back (potential pancreatitis) Vomiting blood or material that looks like coffee grounds Signs of gastroparesis , such as feeling full after eating very small amounts, severe bloating, or vomiting undigested food hours after eating Right upper quadrant pain, fever, or yellowing of skin/eyes , which may indicate gallbladder disease (a known risk with GLP-1 receptor agonists) [7] [8] Patients should contact their healthcare provider within 24-48 hours if they experience moderate vomiting that interferes with daily activities, prevents adequate nutrition or medication intake, or does not improve with conservative measures
In a landmark Phase 2 obesity trial, participants receiving the highest dose achieved: Up to ~24% average weight loss at 48 weeks Weight loss had not yet plateaued at the end of the study Potential for even greater reductions with longer treatment duration For context: Semaglutide (GLP-1): ~15% weight loss Tirzepatide (GIP + GLP-1): ~2123% weight loss Retatrutide (GIP + GLP-1 + Glucagon): ~24%+ weight loss in Phase 2 studies Common side effects were similar to other GLP-1based therapies and included nausea, vomiting, diarrhea, constipation, and abdominal discomfort, primarily during dose escalation
Frequently Asked Questions Does GLP-1 medication directly cause loose skin
Post-training heat can aid relaxation
